Author

I. Erkizia

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:non-human primate· 1

Frequent Co-Authors

B. Clotet· 2 shared D. Perez-Zsolt· 2 shared I. Blanco· 2 shared J. Blanco· 2 shared J. Carrillo· 2 shared J. Segales· 2 shared J. Vergara-Alert· 2 shared M. Noguera-Julian· 2 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

B. Clotet

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Siglec-1 on dendritic cells mediates SARS-CoV-2 trans-infection of target cells while on macrophages triggers proinflammatory responses

D. Perez-Zsolt, J. Munoz Basagoiti, J. Rodo, M. Elousa, D. Raich Regue, C. Risco, M. Sachse, M. Pino, S. Gumber, M. Paiardini, J. Chojnacki, I. Erkizia, X. Muniz, E. Ballana, E. Riveira Munoz, , N. Izquierdo-Useros

This study shows Siglec-1 on APCs mediates SARS-CoV-2 trans-infection and triggers proinflammatory responses, suggesting it as a potential therapeutic target.

bioRxiv · May 11, 2021 · PreprintMicrobiology

Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect after a Drug Repurposing Screen

J. Rodon, J. Munoz-Basagoiti, D. Perez-Zsolt, M. Noguera-Julian, R. Paredes, L. Mateu, C. Quinones, I. Erkizia, I. Blanco, A. Valencia, V. Guallar, J. Carrillo, J. Blanco, J. Segales, B. Clotet, , N. Izquierdo-Useros

This study screens existing drugs to identify potent inhibitors of SARS-CoV-2-induced cytopathic effect and viral replication, finding plitidepsin as the most effective clinically approved drug.

bioRxiv · Apr 23, 2020 · PreprintMicrobiology